Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Neurocrine Bioscienc (NBIX)

Neurocrine Bioscienc (NBIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,061,345
  • Shares Outstanding, K 100,637
  • Annual Sales, $ 1,887 M
  • Annual Income, $ 249,700 K
  • 60-Month Beta 0.37
  • Price/Sales 6.54
  • Price/Cash Flow 47.40
  • Price/Book 4.92
Trade NBIX with:

Options Overview Details

View History
  • Implied Volatility 27.40% ( -2.53%)
  • Historical Volatility 64.31%
  • IV Percentile 21%
  • IV Rank 7.15%
  • IV High 94.83% on 08/06/24
  • IV Low 22.21% on 05/16/24
  • Put/Call Vol Ratio 0.41
  • Today's Volume 482
  • Volume Avg (30-Day) 976
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 24,147
  • Open Int (30-Day) 21,766

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 1.48
  • Number of Estimates 10
  • High Estimate 1.76
  • Low Estimate 1.21
  • Prior Year 0.82
  • Growth Rate Est. (year over year) +80.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
118.04 +3.35%
on 09/10/24
154.87 -21.23%
on 08/23/24
-26.25 (-17.71%)
since 08/19/24
3-Month
118.04 +3.35%
on 09/10/24
157.98 -22.78%
on 08/01/24
-8.87 (-6.78%)
since 06/18/24
52-Week
103.63 +17.72%
on 11/10/23
157.98 -22.78%
on 08/01/24
+7.19 (+6.26%)
since 09/19/23

Most Recent Stories

More News
3 Top Growth Stocks to Buy at a Discount This Month

According to analysts, here are three top-notch mid-cap growth stocks to snag at a discount now.

$IDX : 3,121.68 (+1.62%)
NBIX : 122.58 (+2.28%)
FLR : 47.00 (+2.37%)
$SPX : 5,717.50 (+1.77%)
SON : 55.35 (+0.49%)
Why Neurocrine Biosciences Stock Was Tumbling This Week

The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea.

NBIX : 122.58 (+2.28%)
New Study Reveals How Classical Music Could Revolutionize Depression Care

In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of patients...

ALZN : 1.7800 (+2.89%)
NBIX : 122.58 (+2.28%)
TAK : 14.89 (+0.47%)
AXSM : 95.60 (+4.44%)
BIIB : 201.75 (+2.11%)
Neurocrine: Q2 Earnings Snapshot

Neurocrine: Q2 Earnings Snapshot

NBIX : 122.58 (+2.28%)
Neurocrine: Q1 Earnings Snapshot

Neurocrine: Q1 Earnings Snapshot

NBIX : 122.58 (+2.28%)
Neurocrine: Q4 Earnings Snapshot

Neurocrine: Q4 Earnings Snapshot

NBIX : 122.58 (+2.28%)
Neurocrine: Q3 Earnings Snapshot

Neurocrine: Q3 Earnings Snapshot

NBIX : 122.58 (+2.28%)
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2023 financial results conference call and...

NBIX : 122.58 (+2.28%)
Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints

CAHtalystâ„¢ Pediatric Study Met Primary Endpoint Demonstrating a Statistically Significant Decrease from Baseline in Serum Androstenedione in Children and...

NBIX : 122.58 (+2.28%)
Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the...

NBIX : 122.58 (+2.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding...

See More

Key Turning Points

3rd Resistance Point 126.56
2nd Resistance Point 125.02
1st Resistance Point 122.44
Last Price 122.58
1st Support Level 118.32
2nd Support Level 116.78
3rd Support Level 114.20

See More

52-Week High 157.98
Fibonacci 61.8% 137.22
Fibonacci 50% 130.80
Fibonacci 38.2% 124.39
Last Price 122.58
52-Week Low 103.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar